RiMO-301(RiMO-301) - 药物靶点：IDO1_在研适应症：头颈癌转移，头颈部肿瘤_专利_临床

Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.

开始日期2023-04-03

申办/合作机构

Coordination Pharmaceuticals, Inc.初创企业

[+1]

NCT03444714 / Recruiting临床1期

Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes.
Condition or Disease:
Patient with advanced tumor which is clinically accessible for intratumoral injection
Intervention/Treatment:
Drug - RiMO-301
Radiation - Radiotherapy
Phase:
Phase 1

开始日期2018-04-10

申办/合作机构

Coordination Pharmaceuticals, Inc.初创企业

[+1]

100 项与 RiMO-301 相关的临床结果

登录后查看更多信息

100 项与 RiMO-301 相关的转化医学

登录后查看更多信息

100 项与 RiMO-301 相关的专利（医药）

登录后查看更多信息

100 项与 RiMO-301 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈癌转移	临床2期	美国	Coordination Pharmaceuticals, Inc.初创企业	2023-04-03
头颈癌转移	临床2期	美国	University of Illinois	2023-04-03
头颈部肿瘤	临床2期	美国	University of Illinois	2023-04-03
头颈部肿瘤	临床2期	美国	Coordination Pharmaceuticals, Inc.初创企业	2023-04-03
前列腺癌	临床2期	美国	RiMO Therapeutics LLC	2018-06-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03444714 (ASCO2023) 人工标引	临床1期	肿瘤	25	RiMO-301	(構範鬱鹹齋網選遞構艱) = No protocol defined DLT was reported. 鏇夢製積壓蓋繭簾醖構 (齋壓蓋積壓壓鬱窪醖蓋 ) 更多	积极	2023-05-31